Literature DB >> 26060051

Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma.

Sonali Thosani1, Montserrat Ayala-Ramirez1, Alejandro Román-González2, Shouhao Zhou1, Nirav Thosani1, Annette Bisanz1, Camilo Jimenez3.   

Abstract

OBJECTIVE: Pheochromocytomas (PHs) and sympathetic paragangliomas (PGs) are tumors that produce catecholamines, predisposing patients to cardiovascular disease and gastrointestinal effects such as constipation.
OBJECTIVES: i) determine the prevalence of constipation, its risk factors, and its impact on survival; ii) identify whether a systematic combination of fiber, water, and laxatives was effective for treatment of constipation. DESIGN AND METHODS: We retrospectively studied 396 patients with PH/PG diagnosed in 2005-2014. The study population was patients with constipation as a presenting symptom; the control group was patients without constipation as a presenting symptom. The MD Anderson Symptom Inventory was used to assess constipation and quality of life.
RESULTS: Twenty-three patients (6%) had constipation. Constipation was associated with headaches, palpitations, diaphoresis, weight loss, and excessive noradrenaline production (P<0.0001). Eighteen of these patients had non-metastatic primary tumors larger than 5 cm and/or extensive metastases. No statistically significant differences in age, sex, and genotype were noted between the study and control groups. In patients without metastases, resection of the primary tumor led to symptom disappearance. A systematic combination of fiber, water, and laxatives was associated with symptom improvement. Two patients who presented unmanaged constipation died because of sepsis from toxic megacolon.
CONCLUSIONS: Constipation is a rare and potentially lethal complication in patients with PH/PGs. Severe constipation can be prevented by recognizing and treating mild symptoms.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26060051     DOI: 10.1530/EJE-15-0456

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  15 in total

Review 1.  Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.

Authors:  Paola Jimenez; Claudio Tatsui; Aaron Jessop; Sonali Thosani; Camilo Jimenez
Journal:  Curr Oncol Rep       Date:  2017-10-28       Impact factor: 5.075

Review 2.  PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.

Authors:  Garima Gupta; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443

Review 3.  Supportive management of patients with pheochromocytoma/paraganglioma undergoing noninvasive treatment.

Authors:  Sara Talvacchio; Matthew A Nazari; Karel Pacak
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2022-06-01       Impact factor: 3.626

4.  Pheochromocytoma in Urologic Practice.

Authors:  Nikhil Waingankar; Gennady Bratslavsky; Camilo Jimenez; Paul Russo; Alexander Kutikov
Journal:  Eur Urol Focus       Date:  2016-09-28

Review 5.  New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach.

Authors:  Camilo Jimenez; Guofan Xu; Jeena Varghese; Paul H Graham; Matthew T Campbell; Yang Lu
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

6.  Optimizing Hemodynamics with Transcatheter Arterial Embolization in Adrenal Pheochromocytoma Rupture.

Authors:  Naoki Edo; Takahiro Yamamoto; Satoshi Takahashi; Yamato Mashimo; Koji Morita; Koji Saito; Hiroshi Kondo; Yuko Sasajima; Fukuo Kondo; Hiroko Okinaga; Kazuhisa Tsukamoto; Toshio Ishikawa
Journal:  Intern Med       Date:  2018-02-28       Impact factor: 1.271

7.  Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.

Authors:  S Severi; A Bongiovanni; M Ferrara; S Nicolini; F Di Mauro; M Sansovini; I Lolli; E Tardelli; C Cittanti; V Di Iorio; E Mezzenga; E Scarpi; T Ibrahim; G Paganelli; S Zovato
Journal:  ESMO Open       Date:  2021-06-14

Review 8.  Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer.

Authors:  Camilo Jimenez
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-28       Impact factor: 5.555

9.  Paradoxical hypertension.

Authors:  Sreenivasa Rao Sudulagunta; Monica Kumbhat; Mahesh Babu Sodalagunta; Shiva Kumar Bangalore Raja
Journal:  Oxf Med Case Reports       Date:  2018-07-25

Review 10.  Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.

Authors:  Rodrigo Toledo; Camilo Jimenez
Journal:  F1000Res       Date:  2018-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.